Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.56 |
| ▸ | FLT1 | P17948 | 2/20 | 0.56 |
| ▸ | FLT4 | P35916 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | LOX | P28300 | 4/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325368 | 0.88 | KDR (0.52) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1325348 | 0.88 | KDR (0.75) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1325423 | 0.88 | KDR (0.62) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1325285 | 0.87 | KDR (0.53) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1325008 | 0.87 | KDR (0.59) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL4313245 | 0.86 | KDR (0.44) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1324953 | 0.83 | KDR (0.57) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1324765 | 0.83 | KDR (0.55) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL278840 | 0.82 | KDR (0.78) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL12124621 | 0.82 | KDR (0.52) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058276-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | KDR 1285/4885FLT1 1391/4885FLT4 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.